222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

8 trials found

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-001734-34-NL (EUCTR)	07/04/2020	22/08/2019	Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephrop ...	A randomized, open-label, two-arm, parallel group, proof-of-concept clinical trial to investigate th ...	Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LNP023 HYDROCHLORIDE SALT ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	United States;Czechia;Taiwan;Spain;Russian Federation;United Kingdom;India;France;Argentina;Singapor ...
2	EUCTR2019-001734-34-DE (EUCTR)	30/10/2019	12/09/2019	Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephrop ...	A randomized, open-label, two arm, parallel group, proof-of-concept clinical trial to investigate th ...	Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LNP023 HYDROCHLORIDE SALT ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	United States;Czechia;Taiwan;Spain;Russian Federation;United Kingdom;India;France;Argentina;Singapor ...
3	EUCTR2019-001734-34-FR (EUCTR)	23/10/2019	13/09/2019	Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephrop ...	A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinic ...	Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHL ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	72	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;France;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany ...
4	EUCTR2019-001734-34-GB (EUCTR)	23/09/2019	07/08/2019	Efficacy and safety of LNP023 compared with rituximab in subjects with idiopathic membranous nephrop ...	A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinic ...	Idiopathic Membranous nephropathy MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: ...	Product Code: LNP023 INN or Proposed INN: not yet established Other descriptive name: LNP023 HYDROCHL ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	72	Phase 2	United States;France;Czech Republic;Argentina;Spain;Singapore;Russian Federation;Netherlands;Germany ...
5	EUCTR2018-003437-15-FR (EUCTR)	03/04/2019	27/02/2019	Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome	Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome - RIFIREINS	Minimal Change Nephrotic Syndrome (MCNS) MedDRA version: 20.0;Level: LLT;Classification code 1002916 ...	Trade Name: MabThera Product Name: MabThera INN or Proposed INN: RITUXIMAB INN or Proposed INN: PREDNIS ...	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	148	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France
6	EUCTR2013-000226-55-NL (EUCTR)	04/03/2015	24/06/2014	SEQUENTIAL THERAPY WITH TACROLIMUS AND RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHY	European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequenti ...	Primary membranous nephropathy MedDRA version: 17.0;Level: LLT;Classification code 10027170;Term: Me ...	Trade Name: Tacrolimus Product Name: TACROLIMUS INN or Proposed INN: TACROLIMUS Other descriptive name: ...	Fundacion Renal Iñigo Alvarez Toledo	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	175		Spain;Netherlands
7	EUCTR2011-006115-59-IT (EUCTR)	11/06/2012	08/06/2012	A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of ...	A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of ...	MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoan ...	Trade Name: MABTHERA EV 1FL 50ML 500MG Trade Name: URBASON IM EV 1F 250MG+1F 5ML Trade Name: MEDROL*10 ...	AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
8	EUCTR2008-006750-17-IT (EUCTR)	14/04/2009	27/01/2009	A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission ...	A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission ...	Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glome ...	Trade Name: MABTHERA INN or Proposed INN: Rituximab Trade Name: MABTHERA INN or Proposed INN: Rituximab ...	IST. DI RICERCHE FARMACOLOG. M. NEGRI	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Italy

First Previous1Next Last